Vistin Pharma ASA: Invitation to Q4 2022 conference call

10 Feb 2023 10:00 CET

Oslo, Norway, 10 February 2023

Vistin Pharma ASA will release its fourth quarter and preliminary 2022 results
on Friday 17(th) of February 2023. Vistin Pharma will host a conference call for
all shareholders and interested parties at the same day; Friday 17(th) of
February at 08:30 CET. There will be a Q&A session following the management
discussion.

The conference call will be held in English.

The fourth quarter conference call will be available via web and audio through
the following access points:

Webcast:
https://edge.media-server.com/mmc/p/cuz2jc4e

Telephone conference (online registration):
https://register.vevent.com/register/BI68307a0a256a4fd8b13cef5199b3578c

*****

For further information, please contact:

Alexander Karlsen
CFO
+47 97053621
alexander.karlsen@vistin.com (mailto:alexander.karlsen@vistin.com)


About Vistin Pharma | www.vistin.com

Vistin Pharma is a Norwegian pharmaceutical company producing Metformin
Hydrochloride (API). The Metformin is also available as Direct Compressible
lubricated granules. As a solely dedicated European Metformin producer, Vistin
Pharma is a well-positioned supplier to leading pharmaceutical companies. Vistin
Pharma is headquartered in Oslo, Norway, and has highly qualified employees and
a dedicated manufacturing facility in Kragerø.

More information:
Access the news on Oslo Bors NewsWeb site